A b s t r a c t Objectives:The Clinical Global Impression -Schizophrenia Scale was designed to assess severity and treatment response in subjects with schizophrenia involved in naturalistic studies and daily clinical practice. The objective of this study is to validate the Portuguese version of the Clinical Global Impression -Schizophrenia Scale in Brazil by assessing its psychometric properties. Method: Cross-sectional validation study of the Portuguese version of the Clinical Global Impression -Schizophrenia Scale, tested in outpatients and inpatients with schizophrenia (DSM-IV, ICD-10) from 6 centers in Brazil. Concurrent validity and sensitivity to change were assessed by comparison with the Positive and Negative Syndrome Scale, which is considered the gold standard tool to evaluate patients with schizophrenia. Interrater reliability was evaluated by intraclass correlation coefficients (ICC) calculated based on the scoring of two concomitant raters. Results: 70 inpatients and 70 outpatients were evaluated. Total Clinical Global Impression -Schizophrenia Scale and Positive and Negative Syndrome Scale scores were highly correlated (r = 0.79; p < 0.01). Positive (r = 0.86), negative (r = 0.79), depressive (r = 0.66) and cognitive (r = 0.75) symptoms subscale scores were also correlated between both scales (p < 0.01). Sensitivity to change was significantly correlated between the Clinical Global Impression -Schizophrenia Scale and Positive and Negative Syndrome Scale (r = 0.73; p < 0.01). Interrater reliability was substantial for positive symptoms and total scores of the Clinical Global Impression -Schizophrenia Scale (ICC = 0.81 and 0.73), and moderate for negative, depressive, and cognitive symptoms score (0.64, 0.67 and 0.63, respectively). Conclusions: The Brazilian version of the Clinical Global Impression -Schizophrenia Scale is a valid and reliable instrument for the assessment of severity and treatment response in schizophrenic inpatient and outpatients.Descriptors: Schizophrenia; Psychiatric status rating scales; Validity of tests; Validation studies; Multicenter study Resumo Objetivos: A Escala de Impressão Clínica Global -Esquizofrenia é um instrumento de aplicação simples e rápido, utilizado para avaliar a severidade de sintomas em pacientes com esquizofrenia. Pode ser aplicado em estudos naturalísticos e na prática clínica. O objetivo deste trabalho é estudar as propriedades psicométricas e validar a versão Brasileira da Escala de Impressão Clínica Global -Esquizofrenia em nosso meio. Método: Estudo transversal de validação da Escala de Impressão Clínica GlobalEsquizofrenia, na versão em Português, em pacientes com esquizofrenia, hospitalizados e em tratamento ambulatorial (DSM-IV, ICD-10), selecionados em seis centros no Brasil. Validade concorrente e sensibilidade à mudança foram determinadas em comparação com a escala Positive and Negative Syndrome Scale, considerada padrão-ouro. Confiabilidade interavaliador foi determinada através de coeficientes de correlação intraclasse (ICC), calculados a p...
The Clinical Global Impression-Schizophrenia Scale was designed to assess severity and treatment response in subjects with schizophrenia involved in naturalistic studies and daily clinical practice. The objective of this study is to validate the Portuguese version of the Clinical Global Impression-Schizophrenia Scale in Brazil by assessing its psychometric properties. Method: Cross-sectional validation study of the Portuguese version of the Clinical Global Impression-Schizophrenia Scale, tested in outpatients and inpatients with schizophrenia (DSM-IV, ICD-10) from 6 centers in Brazil. Concurrent validity and sensitivity to change were assessed by comparison with the Positive and Negative Syndrome Scale, which is considered the gold standard tool to evaluate patients with schizophrenia. Interrater reliability was evaluated by intraclass correlation coefficients (ICC) calculated based on the scoring of two concomitant raters. Results: 70 inpatients and 70 outpatients were evaluated. Total Clinical Global Impression-Schizophrenia Scale and Positive and Negative Syndrome Scale scores were highly correlated (r = 0.79; p < 0.01). Positive (r = 0.86), negative (r = 0.79), depressive (r = 0.66) and cognitive (r = 0.75) symptoms subscale scores were also correlated between both scales (p < 0.01). Sensitivity to change was significantly correlated between the Clinical Global Impression-Schizophrenia Scale and Positive and Negative Syndrome Scale (r = 0.73; p < 0.01). Interrater reliability was substantial for positive symptoms and total scores of the Clinical Global Impression-Schizophrenia Scale (ICC = 0.81 and 0.73), and moderate for negative, depressive, and cognitive symptoms score (0.64, 0.67 and 0.63, respectively). Conclusions: The Brazilian version of the Clinical Global Impression-Schizophrenia Scale is a valid and reliable instrument for the assessment of severity and treatment response in schizophrenic inpatient and outpatients.
A autora discute a questão do diagnóstico em psiquiatria, confrontando-o com o diagnóstico em medicina. Critica a tendência atual de se referenciar a psiquiatria no paradigma médico-científico, o que leva à exclusão do sujeito, do psiquiatra e da própria clínica. Propõe o resgate da clínica em suas referências clássicas, aliada à ética do sujeito. Palavras-chave: Psiquiatria, medicina, psicanálise, sujeito, objeto * Texto apresentado no V Congresso Brasileiro de Psicopatologia Fundamental, 15 a 17 de setembro de 2000, Campinas, SP.
A partir da demarcação das diferenças entre o sintoma psiquiátrico e o psicanalítico e da especificidade do psicofármaco dentro da medicina, a autora discute a importância de a psicanálise acompanhar os avanços da psicofarmacologia assim como a importância de não se desvincular os conceitos operativos da psicanálise, tais como a transferência e o conceito de sujeito, do ato de medicar.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.